Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine

about

Evaluating the toxicity of bDtBPP on CHO-K1 cells for testing of single-use bioprocessing systems considering media selection, cell culture volume, mixing, and exposure duration.

P2860

Q47656357-477AB7C7-7FF1-4C22-B8EE-398F01FB0537

P2860

Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine

Item

http://www.wikidata.org/entity/Q36289307

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Bone Marrow and Peripheral Blo ...... he Active Form of Sapacitabine

@ast

Bone Marrow and Peripheral Blo ...... he Active Form of Sapacitabine

@en

type

Item

label

Bone Marrow and Peripheral Blo ...... he Active Form of Sapacitabine

@ast

Bone Marrow and Peripheral Blo ...... he Active Form of Sapacitabine

@en

prefLabel

Bone Marrow and Peripheral Blo ...... he Active Form of Sapacitabine

@ast

Bone Marrow and Peripheral Blo ...... he Active Form of Sapacitabine

@en

P1476

Bone Marrow and Peripheral Blo ...... he Active Form of Sapacitabine

@en

P2093

Kent W Christopherson

http://www.w3.org/2001/XMLSchema#string

Laura A Paganessi

http://www.w3.org/2001/XMLSchema#string

Melissa Larson

http://www.w3.org/2001/XMLSchema#string

Robin R Frank

http://www.w3.org/2001/XMLSchema#string

Sucheta Jagan

http://www.w3.org/2001/XMLSchema#string

P2860

Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells

The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines

Mechanism of action of mitoxantrone.

Potential mechanisms of resistance to cytarabine in AML patients.

Nucleoside analogues: mechanisms of drug resistance and reversal strategies.

High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.

New agents in acute myeloid leukemia and other myeloid disorders.

Targeting the bone marrow microenvironment in hematologic malignancies.

Rationale for the use of mitoxantrone in multiple sclerosis.

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.

P304

727683

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/727683

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P50

Parameswaran Venugopal

P577

2012-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232226656

http://www.w3.org/2001/XMLSchema#string

P698

23049558

http://www.w3.org/2001/XMLSchema#string

P932

3461608

http://www.w3.org/2001/XMLSchema#string

Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine

about

P2860

P2860

Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P932